FDA
-
-
-
-
-
-
-
Revelation Biosciences forms advisory board for kidney injury trial
-
-
-
-
-
-
-
Revelation Biosciences reaches FDA agreement on drug approval pathway
-
-
-
-
-
-
-
Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year
-
-
-
-
-
-
-
Revelation Biosciences reports positive phase 1b study results for CKD drug
-
-
-
-
-
-
-
Revelation Biosciences (REVB) Prices 3.64M Share Offering at $1.10/sh
-
-
-
-
-
-
-
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024
-
-
-
-
-
-
-
Nasdaq Grants Revelation Biosciences Inc. Continued Listing
-
325,297 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

